Literature DB >> 32454616

Quetiapine Fumarate Extended-release Tablet Formulation Design Using Artificial Neural Networks.

Esher Özçelik1, Burcu Mesut1, Buket Aksu2, Yıldız Özsoy1.   

Abstract

OBJECTIVES: This design study was implemented within the scope of the quality by design approach, which included the "International Conference on Harmonization" guidelines. We evaluated the quality of a modified-release tablet formulation of quetiapine fumarate, which was designed using artificial neural networks (ANN), and determined a new formulation that was similar to the reference product.
MATERIALS AND METHODS: Twelve different formulations were produced and tested. The reference product's results and our experimental results were used as outputs for the training of the ANN programs of Intelligensys Ltd.
RESULTS: Dissolution tests were performed with the new formulation (F13) suggested by the INForm V.4 ANN program in three different pHs of the gastrointestinal system. The compliance of this formulation was confirmed by comparing the results with an f2 similarity test.
CONCLUSION: Use of these programs supports research and development processes with multiple evaluation methods and alternative formulations may be determined faster and at lower cost. ©Copyright 2017 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Quetiapine fumarate; artificial neural networks; extended-release tablets; neuro-fuzzy logic; quality by design; wet granulation

Year:  2017        PMID: 32454616      PMCID: PMC7227933          DOI: 10.4274/tjps.97720

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  22 in total

1.  International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice.

Authors: 
Journal:  Fed Regist       Date:  2000-12-29

2.  Investigation of an artificial intelligence technology--Model trees. Novel applications for an immediate release tablet formulation database.

Authors:  Q Shao; R C Rowe; P York
Journal:  Eur J Pharm Sci       Date:  2007-03-12       Impact factor: 4.384

3.  Pharmaceutical quality by design: product and process development, understanding, and control.

Authors:  Lawrence X Yu
Journal:  Pharm Res       Date:  2008-01-10       Impact factor: 4.200

4.  Pharmaceutical granulation and tablet formulation using neural networks.

Authors:  J G Kesavan; G E Peck
Journal:  Pharm Dev Technol       Date:  1996-12       Impact factor: 3.133

5.  Preparation and evaluation of floating tablets of pregabalin.

Authors:  Navjot Kanwar; Rakesh Kumar; Amita Sarwal; V R Sinha
Journal:  Drug Dev Ind Pharm       Date:  2015-07-06       Impact factor: 3.225

6.  A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation.

Authors:  Buket Aksu; Anant Paradkar; Marcel de Matas; Özgen Özer; Tamer Güneri; Peter York
Journal:  Pharm Dev Technol       Date:  2012-08-13       Impact factor: 3.133

7.  Development of sustained release formulation of an antithrombotic drug and application of Fuzzy logic.

Authors:  Celil Tan; İsmail Tuncer Degim
Journal:  Pharm Dev Technol       Date:  2010-11-10       Impact factor: 3.133

8.  Optimization of metformin HCl 500 mg sustained release matrix tablets using Artificial Neural Network (ANN) based on Multilayer Perceptrons (MLP) model.

Authors:  Uttam Mandal; Veeran Gowda; Animesh Ghosh; Anirbandeep Bose; Uttam Bhaumik; Bappaditya Chatterjee; Tapan Kumar Pal
Journal:  Chem Pharm Bull (Tokyo)       Date:  2008-02       Impact factor: 1.645

9.  Xanthan gum: production, recovery, and properties.

Authors:  F García-Ochoa; V E Santos; J A Casas; E Gómez
Journal:  Biotechnol Adv       Date:  2000-11-01       Impact factor: 14.227

10.  Influence of different polymer types on the overall release mechanism in hydrophilic matrix tablets.

Authors:  Anna Körner; Lennart Piculell; Frida Iselau; Bengt Wittgren; Anette Larsson
Journal:  Molecules       Date:  2009-07-24       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.